CONMED Deferred Long Term Asset Charges from 2010 to 2024
| CNMD Stock | USD 74.91 3.20 4.46% |
Deferred Long Term Asset Charges | First Reported 2011-06-30 | Previous Quarter 3.7 M | Current Value 4.7 M | Quarterly Volatility 992.3 K |
Check CONMED financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among CONMED's main balance sheet or income statement drivers, such as Depreciation And Amortization of 31.9 M, Interest Expense of 41.8 M or Selling General Administrative of 531.1 M, as well as many indicators such as Price To Sales Ratio of 2.84, Dividend Yield of 0.0136 or PTB Ratio of 4.23. CONMED financial statements analysis is a perfect complement when working with CONMED Valuation or Volatility modules.
CONMED | Deferred Long Term Asset Charges |
Latest CONMED's Deferred Long Term Asset Charges Growth Pattern
Below is the plot of the Deferred Long Term Asset Charges of CONMED over the last few years. It is CONMED's Deferred Long Term Asset Charges historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in CONMED's overall financial position and show how it may be relating to other accounts over time.
| Deferred Long Term Asset Charges | 10 Years Trend |
|
Deferred Long Term Asset Charges |
| Timeline |
CONMED Deferred Long Term Asset Charges Regression Statistics
| Arithmetic Mean | 3,527,717 | |
| Geometric Mean | 3,032,945 | |
| Coefficient Of Variation | 48.19 | |
| Mean Deviation | 1,522,440 | |
| Median | 4,721,000 | |
| Standard Deviation | 1,700,142 | |
| Sample Variance | 2.9T | |
| Range | 4.6M | |
| R-Value | 0.86 | |
| Mean Square Error | 805.2B | |
| R-Squared | 0.74 | |
| Significance | 0.000038 | |
| Slope | 327,322 | |
| Total Sum of Squares | 40.5T |
CONMED Deferred Long Term Asset Charges History
About CONMED Financial Statements
CONMED stakeholders use historical fundamental indicators, such as CONMED's Deferred Long Term Asset Charges, to determine how well the company is positioned to perform in the future. Although CONMED investors may analyze each financial statement separately, they are all interrelated. For example, changes in CONMED's assets and liabilities are reflected in the revenues and expenses on CONMED's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in CONMED. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Deferred Long Term Asset Charges | 5.4 M | 5.7 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether CONMED is a strong investment it is important to analyze CONMED's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact CONMED's future performance. For an informed investment choice regarding CONMED Stock, refer to the following important reports:Check out the analysis of CONMED Correlation against competitors. For information on how to trade CONMED Stock refer to our How to Trade CONMED Stock guide.You can also try the Cryptocurrency Center module to build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of CONMED. If investors know CONMED will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about CONMED listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 2.14 | Dividend Share 0.8 | Earnings Share 4.22 | Revenue Per Share 41.821 | Quarterly Revenue Growth 0.04 |
The market value of CONMED is measured differently than its book value, which is the value of CONMED that is recorded on the company's balance sheet. Investors also form their own opinion of CONMED's value that differs from its market value or its book value, called intrinsic value, which is CONMED's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because CONMED's market value can be influenced by many factors that don't directly affect CONMED's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between CONMED's value and its price as these two are different measures arrived at by different means. Investors typically determine if CONMED is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, CONMED's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.